Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

被引：184
|
作者：
Amatu, A. [1 ]
Sartore-Bianchi, A. [1 ,2 ]
Bencardino, K. [1 ]
Pizzutilo, E. G. [1 ,2 ]
Tosi, F. [1 ,2 ]
Siena, S. [1 ,2 ]
机构：
[1] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Dept Hematol & Oncol, Piazza Osped Maggiore 3, I-20162 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
欧盟地平线“2020”;
关键词：
TRK; tropomyosin receptor kinase; NTRK gene fusions; TRK fusion cancer; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESOBLASTIC NEPHROMA; TARGETED THERAPY; CONGENITAL INSENSITIVITY; INHIBITOR ENTRECTINIB; PROTOONCOGENE PRODUCT; ACQUIRED-RESISTANCE; HIGH-FREQUENCY;
D O I：
10.1093/annonc/mdz383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.
引用
收藏
页码：VIII5 / VIII15
页数：11
相关论文
共 50 条
  • [1] Neurotrophic receptor tyrosine kinase (NTRK) fusions and their role in cancer
    Ruiz-Cordero, Roberto
    Ng, Dianna L.
    CANCER CYTOPATHOLOGY, 2020, 128 (11) : 775 - 779
  • [2] Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
    Jiang, Tingting
    Wang, Guan
    Liu, Yao
    Feng, Lu
    Wang, Meng
    Liu, Jie
    Chen, Yi
    Ouyang, Liang
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (02) : 355 - 372
  • [3] Development of small-molecule tropomyosin receptor kinase(TRK) inhibitors for NTRK fusion cancers
    Tingting Jiang
    Guan Wang
    Yao Liu
    Lu Feng
    Meng Wang
    Jie Liu
    Yi Chen
    Liang Ouyang
    ActaPharmaceuticaSinicaB, 2021, 11 (02) : 355 - 372
  • [4] Identification of tropomyosin kinase receptor (TRK) mutations in cancer.
    Nanda, Nisha
    Fennell, Tim
    Low, Jennifer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
    Laetsch, Theodore W.
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4974 - 4982
  • [6] Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients
    Durzynska, Monika
    Michalek, Irmina M.
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (01): : 15 - 21
  • [7] Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
    Wong, Derek
    Yip, Stephen
    Sorensen, Poul H.
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1385 - 1399
  • [8] Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
    Federman, Noah
    McDermott, Ray
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 931 - 939
  • [9] Association of Pan-TRK immunohistochemistry expression with NTRK and other gene fusions in thyroid cancer
    Jung, C. K.
    Park, J. M.
    Jung, S.
    Kim, S. Y.
    Jeon, S.
    Chung, Y.
    VIRCHOWS ARCHIV, 2024, 485 : S74 - S75
  • [10] Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes
    Chetty, Runjan
    JOURNAL OF CLINICAL PATHOLOGY, 2019, 72 (03) : 187 - 190
12345